Lindsey Kennedy1, Vik Meadows1, Amelia Sybenga2, Jennifer Demieville3, Lixian Chen1, Laura Hargrove4, Burcin Ekser5, Wasim Dar6, Ludovica Ceci1, Debjyoti Kundu1, Konstantina Kyritsi1, Linh Pham1, Tianhao Zhou4, Shannon Glaser4, Fanyin Meng1,7, Gianfranco Alpini1,7, Heather Francis1,7. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN. 2. Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN. 3. Central Texas Veterans Health Care System, Texas A&M University College of Medicine, Bryan, TX. 4. Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX. 5. Department of Transplant Surgery, Indiana University School of Medicine, Indianapolis, IN. 6. Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Health Science Center at Houston, Houston, TX. 7. Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN.
Abstract
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is simple steatosis but can develop into nonalcoholic steatohepatitis (NASH), characterized by liver inflammation, fibrosis, and microvesicular steatosis. Mast cells (MCs) infiltrate the liver during cholestasis and promote ductular reaction (DR), biliary senescence, and liver fibrosis. We aimed to determine the effects of MC depletion during NAFLD/NASH. APPROACH AND RESULTS: Wild-type (WT) and KitW-sh (MC-deficient) mice were fed a control diet (CD) or a Western diet (WD) for 16 weeks; select WT and KitW-sh WD mice received tail vein injections of MCs 2 times per week for 2 weeks prior to sacrifice. Human samples were collected from normal, NAFLD, or NASH mice. Cholangiocytes from WT WD mice and human NASH have increased insulin-like growth factor 1 expression that promotes MC migration/activation. Enhanced MC presence was noted in WT WD mice and human NASH, along with increased DR. WT WD mice had significantly increased steatosis, DR/biliary senescence, inflammation, liver fibrosis, and angiogenesis compared to WT CD mice, which was significantly reduced in KitW-sh WD mice. Loss of MCs prominently reduced microvesicular steatosis in zone 1 hepatocytes. MC injection promoted WD-induced biliary and liver damage and specifically up-regulated microvesicular steatosis in zone 1 hepatocytes. Aldehyde dehydrogenase 1 family, member A3 (ALDH1A3) expression is reduced in WT WD mice and human NASH but increased in KitW-sh WD mice. MicroRNA 144-3 prime (miR-144-3p) expression was increased in WT WD mice and human NASH but reduced in KitW-sh WD mice and was found to target ALDH1A3. CONCLUSIONS: MCs promote WD-induced biliary and liver damage and may promote microvesicular steatosis development during NAFLD progression to NASH through miR-144-3p/ALDH1A3 signaling. Inhibition of MC activation may be a therapeutic option for NAFLD/NASH treatment.
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is simple steatosis but can develop into nonalcoholic steatohepatitis (NASH), characterized by liver inflammation, fibrosis, and microvesicular steatosis. Mast cells (MCs) infiltrate the liver during cholestasis and promote ductular reaction (DR), biliary senescence, and liver fibrosis. We aimed to determine the effects of MC depletion during NAFLD/NASH. APPROACH AND RESULTS: Wild-type (WT) and KitW-sh (MC-deficient) mice were fed a control diet (CD) or a Western diet (WD) for 16 weeks; select WT and KitW-sh WD mice received tail vein injections of MCs 2 times per week for 2 weeks prior to sacrifice. Human samples were collected from normal, NAFLD, or NASH mice. Cholangiocytes from WT WD mice and human NASH have increased insulin-like growth factor 1 expression that promotes MC migration/activation. Enhanced MC presence was noted in WT WD mice and human NASH, along with increased DR. WT WD mice had significantly increased steatosis, DR/biliary senescence, inflammation, liver fibrosis, and angiogenesis compared to WT CD mice, which was significantly reduced in KitW-sh WD mice. Loss of MCs prominently reduced microvesicular steatosis in zone 1 hepatocytes. MC injection promoted WD-induced biliary and liver damage and specifically up-regulated microvesicular steatosis in zone 1 hepatocytes. Aldehyde dehydrogenase 1 family, member A3 (ALDH1A3) expression is reduced in WT WD mice and human NASH but increased in KitW-sh WD mice. MicroRNA 144-3 prime (miR-144-3p) expression was increased in WT WD mice and human NASH but reduced in KitW-sh WD mice and was found to target ALDH1A3. CONCLUSIONS: MCs promote WD-induced biliary and liver damage and may promote microvesicular steatosis development during NAFLD progression to NASH through miR-144-3p/ALDH1A3 signaling. Inhibition of MC activation may be a therapeutic option for NAFLD/NASH treatment.
Authors: Ronald Schilderink; Caroline Verseijden; Jurgen Seppen; Vanesa Muncan; Gijs R van den Brink; Tim T Lambers; Eric A van Tol; Wouter J de Jonge Journal: Am J Physiol Gastrointest Liver Physiol Date: 2016-05-05 Impact factor: 4.052
Authors: Tuyen N M Hua; Jun Namkung; Ai N H Phan; Vu T A Vo; Min-Kyu Kim; Yangsik Jeong; Jong-Whan Choi Journal: J Recept Signal Transduct Res Date: 2018-06-06 Impact factor: 2.092
Authors: Valerio Azzimato; Jennifer Jager; Ping Chen; Cecilia Morgantini; Laura Levi; Emelie Barreby; André Sulen; Carolina Oses; Joost Willerbrords; Connie Xu; Xidan Li; Joanne X Shen; Naveed Akbar; Lars Haag; Ewa Ellis; Kerstin Wålhen; Erik Näslund; Anders Thorell; Robin P Choudhury; Volker M Lauschke; Mikael Rydén; Siobhan M Craige; Myriam Aouadi Journal: Sci Transl Med Date: 2020-02-26 Impact factor: 17.956
Authors: Paulina Pettinelli; Bianca M Arendt; Anastasia Teterina; Ian McGilvray; Elena M Comelli; Scott K Fung; Sandra E Fischer; Johane P Allard Journal: PLoS One Date: 2018-10-31 Impact factor: 3.240